Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death.

Cell metabolism | 2018

The inhibitory effects of cancer on T cell metabolism have been well established, but the metabolic impact of immunotherapy on tumor cells is poorly understood. Here, we developed a CD4+ T cell-based adoptive immunotherapy protocol that was curative for mice with implanted colorectal tumors. By conducting metabolic profiling on tumors, we show that adoptive immunotherapy profoundly altered tumor metabolism, resulting in glutathione depletion and accumulation of reactive oxygen species (ROS) in tumor cells. We further demonstrate that T cell-derived tumor necrosis factor alpha (TNF-α) can synergize with chemotherapy to intensify oxidative stress and tumor cell death in an NADPH (nicotinamide adenine dinucleotide phosphate hydrogen) oxidase-dependent manner. Reduction of oxidative stress, by preventing TNF-α-signaling in tumor cells or scavenging ROS, antagonized the therapeutic effects of adoptive immunotherapy. Conversely, provision of pro-oxidants after chemotherapy can partially recapitulate the antitumor effects of T cell transfer. These findings imply that reinforcing tumor oxidative stress represents an important mechanism underlying the efficacy of adoptive immunotherapy.

Pubmed ID: 29887396 RIS Download

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: R01 CA211229
  • Agency: NCI NIH HHS, United States
    Id: R01 CA182518
  • Agency: NCI NIH HHS, United States
    Id: P01 CA065493
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL118979
  • Agency: NCI NIH HHS, United States
    Id: R01 CA062130
  • Agency: NHLBI NIH HHS, United States
    Id: R01 HL134934
  • Agency: NCI NIH HHS, United States
    Id: R01 CA133085
  • Agency: NCI NIH HHS, United States
    Id: R01 CA103320
  • Agency: NCI NIH HHS, United States
    Id: R01 CA215523
  • Agency: NCI NIH HHS, United States
    Id: R01 CA132640
  • Agency: NCI NIH HHS, United States
    Id: R01 CA158202
  • Agency: NCI NIH HHS, United States
    Id: R01 CA072669

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


CD31 (antibody)

RRID:AB_397095

This monoclonal targets CD31

View all literature mentions

InVivoPlus anti-mouse Ly6G/Ly6C (Gr-1) (antibody)

RRID:AB_10312146

This monoclonal targets Ly6G/Ly6C (Gr-1)

View all literature mentions

InVivoPlus anti-mouse TNFα (antibody)

RRID:AB_1107764

This monoclonal targets TNFα

View all literature mentions

APC anti-mouse CD45.2 (antibody)

RRID:AB_389211

This monoclonal targets CD45.2

View all literature mentions

TNF (antibody)

RRID:AB_10563769

This monoclonal targets TNF

View all literature mentions

FITC anti-mouse CD4 (antibody)

RRID:AB_312691

This monoclonal targets CD4

View all literature mentions